Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
$229K Sell
712
-20
-3% -$6.54K 0.15% 65
2024
Q2
$229K Buy
732
+4
+0.5% +$1.18K 0.16% 61
2024
Q1
$207K Sell
728
-739
-50% -$216K 0.15% 68
2023
Q4
$423K Hold
1,467
0.33% 36
2023
Q3
$394K Buy
1,467
+51
+4% +$12.7K 0.34% 36
2023
Q2
$314K Buy
1,416
+1
+0.1% +$232 0.27% 46
2023
Q1
$342K Buy
1,415
+1
+0.1% +$245 0.31% 39
2022
Q4
$371K Buy
+1,414
New +$379K 0.35% 34

Other funds holding AMGN

Hyperion Partners's AMGN Position: Q3 2024 in Review

Hyperion Partners reduced its Amgen (AMGN) stake by 2.7% in Q3 2024, selling an estimated $6.54K and leaving 712 shares worth $229K. The position accounts for 0.15% of the portfolio, ranked #65.

Hyperion Partners first reported a position in AMGN in Q4 2022 and has held it in 8 quarters since. The position peaked at $423K in Q4 2023. 2,828 funds tracked by Wall St. Rank hold AMGN as of Q3 2024.

  • Hyperion Partners held 712 shares of Amgen worth $229K as of Q3 2024.
  • Hyperion Partners sold 20 Amgen shares in Q3 2024, an estimated $6.54K.
  • Amgen made up 0.15% of Hyperion Partners's portfolio in Q3 2024, its #65 holding.
  • Hyperion Partners first reported a position in Amgen in Q4 2022 and has held it in 8 quarters since.
  • Hyperion Partners's Amgen position peaked at $423K in Q4 2023.
  • 2,828 funds tracked by Wall St. Rank held Amgen as of Q3 2024.

Based on Hyperion Partners's 13F filing for Q3 2024, filed 9 Oct 2024.